Female Breast Cancer Clinical Trial
Official title:
Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1)
The purpose of this study is to evaluate a side effect prevention training (SEPT) that optimizes patients' response expectations before the start of adjuvant endocrine treatment (AET) to prevent nocebo side effects and enhance quality of life during longer term drug intake.
The majority of breast cancer patients discontinue today's standard adjuvant treatment (endocrine therapy) due to side effects and reduced quality of life. Thereby, most side effects are unspecific, thus, not related to the specific pharmacological action of the drug, but to the individual treatment context and patients´ expectations (nocebo effects). The aim of this study is to evaluate a side effect prevention training (SEPT) that optimizes patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during longer term drug intake. Using a randomized trial, we will study the time course of response expectations and side effects in breast cancer patients receiving either SEPT, standard medical care or an attention-control intervention ("supportive therapy") before the start of adjuvant endocrine therapy. We will analyze the effects of changing pre-treatment expectations on cancer-treatment related side effects, quality of life and adherence 3 and 6 months after the start of endocrine therapy. Moderator analyses will be used to determine predictors of non-specific medication side effects and patients that are at high risk of experiencing them. Furthermore, we will explore the mediating influence of coping behaviours, thereby providing insights into pathways of clinical nocebo effects. The study findings promise significant advances in the clinical application of nocebo research with strong implications for clinical and research practice. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
| Completed |
NCT05000502 -
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
|
N/A | |
| Not yet recruiting |
NCT04863833 -
Tomosymthesis for Breast Mass Lesion Characterization
|
||
| Withdrawn |
NCT06145399 -
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
|
Early Phase 1 | |
| Suspended |
NCT01320488 -
Breast Cancer in Young Women: Is it Different?
|
N/A | |
| Recruiting |
NCT02089854 -
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
|
Phase 4 | |
| Recruiting |
NCT06144164 -
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT06331793 -
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
|
N/A | |
| Recruiting |
NCT05439499 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 | |
| Terminated |
NCT03836872 -
Acupuncture for Joint Symptoms in Patients With Breast Cancer
|
N/A | |
| Recruiting |
NCT06332976 -
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
|
||
| Completed |
NCT01671319 -
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06092892 -
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
|
Phase 2 | |
| Recruiting |
NCT05586256 -
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
|
||
| Not yet recruiting |
NCT03153631 -
Female Sexual Dysfunction in Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03059875 -
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
|
N/A | |
| Active, not recruiting |
NCT02088710 -
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
|
N/A | |
| Terminated |
NCT01083641 -
Estrogen for Triple Negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05374161 -
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
|
N/A | |
| Recruiting |
NCT05438810 -
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
|
Phase 3 |